Tetreault Lindsay, Kopjar Branko, Côté Pierre, Arnold Paul, Fehlings Michael G
Toronto Western Hospital, University of Toronto, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. E-mail address for L. Tetreault:
University of Washington, 4333 Brooklyn Avenue N.E., Suite 1400/#315, Box 359455, Seattle, WA 98185. E-mail address:
J Bone Joint Surg Am. 2015 Dec 16;97(24):2038-46. doi: 10.2106/JBJS.O.00189.
Cervical spondylotic myelopathy (CSM) is a progressive spinal condition that is often managed surgically. Knowledge of important predictors of surgical outcome can provide decision support to surgeons and enable them to effectively manage their patients' expectations. The purpose of this study was to identify the most important clinical predictors of surgical outcome in patients with CSM using data from two multinational prospective studies.
A total of 757 patients treated surgically for CSM participated in either the CSM-North America or the CSM-International study. The model was designed to distinguish between patients who achieved a modified Japanese Orthopaedic Association (mJOA) score of ≥16 at the one-year follow-up and those who did not (mJOA < 16). A score of 16 was chosen as the cutoff as an mJOA of ≥16 translates to minimal impairment. Univariate analyses evaluated the relationship between outcome and various clinical predictors. Multivariate Poisson regression was used to create the final prediction rule and estimate relative risks.
Based on univariate analyses, the probability of achieving a score of ≥16 decreased with the presence of certain symptoms, including gait dysfunction, the presence of certain signs such as lower limb spasticity, positive smoking status, higher comorbidity score, more severe preoperative myelopathy, and older age. The final model consisted of six significant and clinically relevant predictors: baseline severity score (relative risk [RR], 1.11; 95% confidence interval [CI], 1.07 to 1.15), impaired gait (RR, 0.76 [ref. = absence]; 95% CI, 0.66 to 0.88), age (RR, 0.91 per decade; 95% CI, 0.85 to 0.96), comorbidity score (RR, 0.93; 95% CI, 0.88 to 0.98), smoking status (RR, 0.78 [ref. = non-smoking]; 95% CI, 0.65 to 0.93), and duration of symptoms (RR, 0.95; 95% CI, 0.90 to 0.99).
Patients were more likely to achieve a score of ≥16 (indicating minimal impairment) if they were younger, had milder preoperative myelopathy, did not smoke, had fewer and less severe comorbidities, did not present with impaired gait, and had shorter symptom duration.
脊髓型颈椎病(CSM)是一种进展性脊柱疾病,通常采用手术治疗。了解手术结果的重要预测因素可为外科医生提供决策支持,并使他们能够有效管理患者的预期。本研究的目的是利用两项跨国前瞻性研究的数据,确定脊髓型颈椎病患者手术结果的最重要临床预测因素。
共有757例接受CSM手术治疗的患者参与了CSM北美研究或CSM国际研究。该模型旨在区分在一年随访时改良日本骨科协会(mJOA)评分≥16分的患者和未达到该评分(mJOA < 16)的患者。选择16分作为临界值,因为mJOA≥16分意味着最小程度的损伤。单因素分析评估了结果与各种临床预测因素之间的关系。多变量泊松回归用于创建最终预测规则并估计相对风险。
基于单因素分析,出现某些症状(包括步态功能障碍)、存在某些体征(如下肢痉挛)、吸烟状态为阳性、合并症评分较高、术前脊髓病更严重以及年龄较大时,获得≥16分的概率会降低。最终模型由六个显著且与临床相关的预测因素组成:基线严重程度评分(相对风险[RR],1.11;95%置信区间[CI],1.07至1.15)、步态受损(RR,0.76[参考 = 无];95%CI,0.66至0.88)、年龄(RR,每十年0.91;95%CI,0.85至0.96)、合并症评分(RR,0.93;95%CI,0.88至0.98)、吸烟状态(RR,0.78[参考 = 不吸烟];95%CI,0.65至0.93)以及症状持续时间(RR,0.95;95%CI,0.90至0.99)。
如果患者年龄较小、术前脊髓病较轻、不吸烟、合并症较少且不太严重、没有步态受损且症状持续时间较短,则更有可能获得≥16分(表明最小程度的损伤)。